Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy (TAHOE)

This study has been completed.
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Clifton O Bingham, Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT00886795
First received: April 22, 2009
Last updated: December 17, 2015
Last verified: December 2015
Results First Received: August 31, 2015  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Urticaria
Intervention: Drug: abatacept (Orencia ®)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Abatacept

4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 weeks, and 8 weeks.

abatacept (Orencia ®): 4 infusions of abatacept administered intravenously at baseline, 2 weeks, 4 week, and 8 weeks. The dose of abatacept received by each participant was based on weight. Participants received either 500mg, 750mg , or 1000mg of abatacept based on weights of >60 kg, 60-100kg, or 100 kg respectively.


Participant Flow:   Overall Study
    Abatacept  
STARTED     4  
COMPLETED     3  
NOT COMPLETED     1  
Lack of Efficacy                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Abatacept

4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 weeks, and 8 weeks.

abatacept (Orencia ®): 4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 week, and 8 weeks.The dose of abatacept received by each participant was based on weight. Participants received either 500mg, 750mg , or 1000mg of abatacept based on weights of >60 kg, 60-100kg, or 100 kg respectively.


Baseline Measures
    Abatacept  
Number of Participants  
[units: participants]
  4  
Age  
[units: years]
Mean (Standard Deviation)
  43  (7.29)  
Gender  
[units: participants]
 
Female     2  
Male     2  
Region of Enrollment  
[units: participants]
 
United States     4  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With Adverse Events   [ Time Frame: baseline, 3 month and 6 months ]

2.  Secondary:   Number of Participants With Clinically Detectable Improvement   [ Time Frame: at each visit and at 3 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Open Label study. Small number of patients. Outcome measures for urticaria not standardized.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Clifton O. Bingham III, M.D.
Organization: Johns Hopkins University
phone: 410-550-0578
e-mail: cbingha2@jhmi.edu


No publications provided


Responsible Party: Clifton O Bingham, Johns Hopkins University
ClinicalTrials.gov Identifier: NCT00886795     History of Changes
Other Study ID Numbers: Tahoe-001
Study First Received: April 22, 2009
Results First Received: August 31, 2015
Last Updated: December 17, 2015
Health Authority: United States: Food and Drug Administration